|Venue||Irish Management Institute, Sandyford, Dublin|
|Date||Wednesday, September 13th , 2023|
|Time||9:30 am - 4:00 pm|
The PMI’s next masterclass will explore the changes and continued developments around the HTA process in Ireland, including an update on ongoing developments at an EU level from
Dr. Roisin Adams, Chair of the HTACG. Key stakeholders including the NCPE will also provide insights and best practice on current HTA processes and submissions in Ireland.
The masterclass will take place on September 13th at the IMI campus in Sandyford.
This timely and topical one-day masterclass will update attendees on the advancing EU HTA regulations, as well as outlining common pitfalls in HTA submissions and how to best to navigate the reimbursement process for HTA applications. With a changing pharma economics landscape placing new demands on market access and external affairs teams, our panel of expert speakers will discuss the future landscape of HTA market access, best practice in HTA submissions – as well as examining what the future of a common HTA application across Europe will look like.
Who should attend?
This one-day masterclass is designed for those working within the market access and external affairs area of the industry.
It will be best suited to Market Access Managers/Directors, External Affairs Leads and/or HEOR professionals.
The masterclasses are designed to be a highly immersive and interactive learning tool. Numbers are kept small to allow for engagement and discussions. There will be a mix of expert speakers from the NCPE and industry which will bring together market access professionals to share their insights, experience and knowledge with the room. This masterclass will also provide an excellent opportunity to share best practices and discuss ideas with fellow Market Access professionals in other companies allowing you to build a strong professional network with peers.
Dr Roisin Adams, Head of HTA Strategy and External Engagement – NCPE
Roisin led the HTA team for a number of years before being seconded to the HSE to lead a new unit tasked with overseeing and managing high cost drugs in acute hospitals.
She is the elected Chair of the Health Technology Assessment Coordination Group which is the governance body responsible for the EU HTA Regulation.
Roisin also co-chairs the HTA domain of the BeNeLuxA initiative and is a Director on the Board of the International Horizon Scanning Initiative. She has been awarded a number of grants from the Health Research Board to examine health preferences in Ireland. Her areas of interest include methods for preference elicitation, combining different data for evidence synthesis and reimbursement mechanisms for high cost drugs.
Brenda Dooley, Founder & CEO – AXIS Consulting
Brenda Dooley founded AXIS Consulting in early 2012. As an experienced market access strategist with 20+ years of international biopharma industry experience, Brenda and her team have developed over 100 bespoke and high-quality reimbursement submissions for the Irish authorities. As Chief Executive at AXIS, Brenda has led the company to its position as the dominant provider for submissions to the Irish authorities and is now leading the expansion of the company into the UK providing HTA submissions to to NICE/SMC/AWMSG.
The purpose of AXIS Consulting is to provide unhindered access for patients to effective health interventions, achieved through agile and nimble strategic engagement with national level reimbursement process. It is the vision of AXIS to be the partner of choice for a selected & aligned customer base – delivering expertly customised UK & Ireland reimbursement submissions.
Des Lucey, Head of Market Access – GSK
Des has held the role of Head of Market Access at GSK Ireland since 2020. Prior to his current role, Des worked as Senior Health Economist in the HTA Directorate of the Health Information and Quality Authority (HIQA), and Senior Pharmacist in the Corporate Pharmaceutical Unit of the Health Service Executive.
Des leads the Market Access Team in GSK Ireland, and is responsible for the development, management and timely delivery of the pricing and market access strategy for GSK medicines and vaccines, & ViiV Healthcare medicines.
Des is currently a member of the Irish Pharmaceutical Healthcare Association (IPHA) Market Access Advisory Forum and the Cancer Care Partnership Group. He supported and advised the IPHA negotiations team for the development of the new IPHA Framework Agreement with the State in 2021. He was recently the sole industry speaker at the first Patient Access Conference in Ireland in February 2023. He possesses a BSc. in Pharmacy from Trinity College Dublin, a Masters in Business Administration (MBA) from University College Cork, and a Masters in Health Economics, Policy and Management (HEPM) from the London School of Economics and Political Sciences.
Pascal Derrien, Chief Executive Officer – Migraine Ireland
Originally from France, Pascal arrived in Ireland in 1998. He is the current CEO with Migraine Ireland, a role he has held since July 2021. Pascal has vast experience in patient advocacy having worked with several large corporations, Not For Profit, Charities and Social Enterprises.
For the last number of years, he has been focusing Social Enterprise & Charity projects leveraging and applying skills acquired in the corporate world over the last 3 decades. Pascal is a Board Member and vice chair of the Neurological Alliance of Ireland (NAI) and as well as an IPPOSI (Irish Platform for Patient Organisations Science and Industry), Board member leading the digital transformation stream.
Mohamed Zein, Health Economics and Decision Modelling Consultant – AXIS Consulting
Mohamed joined AXIS Consulting in 2023; he holds dual degrees: an MSc (Hons) in Pharmacy from Kingston University in London, and an MSc in Health Economics and Decision Modelling from the University of Sheffield. Before joining AXIS, Mohamed practised as a clinical pharmacist for 5-years, during which time he simultaneously worked in health economics and market access for 2.5 years, and has a vast amount of experience, comprising the development of high-quality submission dossiers to stakeholders in the U.K, Europe, and US Markets, covering a multitude of therapeutic areas including orphan and ultra-orphan disease technologies.
This masterclass is proudly supported by:
Online bookings are not available or you are logged out.